Oxysophocarpine attenuates inflammatory osteolysis by modulating the NF-κb pathway and the reactive oxygen species-related Nrf2 signaling pathway.
Xiaofeng ShiTian GaoChaohong YuShaotian FuTingxian GuoWei XuXiaojun LiYitian WangJingwei ZhangXinlin JiaYuan-Qing MaoPublished in: Inflammopharmacology (2024)
OSC could be regarded as an innovative medication for the treatment of osteoclast-associated inflammatory osteolytic diseases.